Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome

Bibliography

• Grundy SM, Cleeman JI, Daniels SR, Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet P, Shaw J. The metabolic syndrome – a new worldwide definition. Lancet 2005;366:1059-62
   PubMed Web of Science ®Google Scholar
• Alberti KG, Eckel RH, Grundy SM, Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5
   PubMed Web of Science ®Google Scholar
• Kotronen A, Westerbacka J, Bergholm R, Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 2007;92:3490-7
   PubMed Web of Science ®Google Scholar
• Marchesini G, Brizi M, Bianchi G, Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-50
   PubMed Web of Science ®Google Scholar
• Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008;51:1947-53
   PubMed Web of Science ®Google Scholar
• Hamaguchi M, Kojima T, Takeda N, The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005;143:722-8
   PubMed Web of Science ®Google Scholar
• Oh SY, Cho YK, Kang MS, The association between increased alanine aminotransferase activity and metabolic factors in nonalcoholic fatty liver disease. Metabolism 2006;55:1604-9
   PubMed Web of Science ®Google Scholar
• Suzuki A, Angulo P, Lymp J, Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology 2005;41:64-71
   PubMed Web of Science ®Google Scholar
• Liangpunsakul S, Chalasani N. Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). Am J Med Sci 2005;329:111-16
   PubMed Web of Science ®Google Scholar
• Marchesini G, Bugianesi E, Forlani G, Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23
   PubMed Web of Science ®Google Scholar
• Fracanzani AL, Valenti L, Bugianesi E, Risk of severe liver disease in NAFLD with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008;48:792-8
   PubMed Web of Science ®Google Scholar
• McMillan KP, Kuk JL, Church TS, Independent associations between liver fat, visceral adipose tissue, and metabolic risk factors in men. Appl Physiol Nutr Metab 2007;32:265-72
   PubMed Web of Science ®Google Scholar
• Day CP, James OFW. Steatohepatitis: a tale of two 'hits'. Gastroenterology 1998;114:842-5
   PubMed Web of Science ®Google Scholar
• Bugianesi E, Manzini P, D'Antico S, Relative contribution of iron burden, HFE mutations and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004;39:179-87
   PubMed Web of Science ®Google Scholar
• Kelley DE, McKolanis TM, Hegazi RA, Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 2003;285:E906-16
   PubMed Web of Science ®Google Scholar
• Fassio E, Alvarez E, Dominguez N, Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004;40:820-6
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Yang L, McCall S, Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007;45:1366-74
   PubMed Web of Science ®Google Scholar
• Wadden TA, Butryn ML, Wilson C. Lifestyle modification for the management of obesity. Gastroenterology 2007;132:2226-38
   PubMed Web of Science ®Google Scholar
• Wing RR; for the Look AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010;170:1566-75
   PubMed Web of Science ®Google Scholar
• Phelan S, Wadden TA, Berkowitz RI, Impact of weight loss on the metabolic syndrome. Int J Obes (Lond) 2007;31:1442-8
   PubMed Web of Science ®Google Scholar
• Case CC, Jones PH, Nelson K, Impact of weight loss on the metabolic syndrome. Diabetes Obes Metab 2002;4:407-14
   PubMedGoogle Scholar
• Muzio F, Mondazzi L, Sommariva D, Long-term effects of low-calorie diet on the metabolic syndrome in obese nondiabetic patients. Diabetes Care 2005;28:1485-6
   Google Scholar
• Tuomilehto J, Lindstrom J, Eriksson JG, Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50
   PubMed Web of Science ®Google Scholar
• Orchard TJ, Temprosa M, Goldberg R, The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005;142:611-19
   PubMed Web of Science ®Google Scholar
• Wing RR, Lang W, Wadden TA, Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011;34:1481-6
   PubMed Web of Science ®Google Scholar
• Writing group of the PREMIER Collaborative Research Group. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA 2003;289:2083-93
   PubMed Web of Science ®Google Scholar
• Romeo S, Kozlitina J, Xing C, Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461-5
   PubMed Web of Science ®Google Scholar
• Huang MA, Greenson JK, Chao C, One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005;100:1072-81
   PubMed Web of Science ®Google Scholar
• Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009;49:306-17
   PubMed Web of Science ®Google Scholar
• Suzuki A, Lindor K, St Sauver J, Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 2005;43:1060-6
   PubMed Web of Science ®Google Scholar
• Hickman IE, Jonsson JR, Prins JB, Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004;53:413-19
   PubMed Web of Science ®Google Scholar
• Promrat K, Kleiner DE, Niemeier HM, Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010;51:121-9
   PubMed Web of Science ®Google Scholar
• Moscatiello S, Di Luzio R, Bugianesi E, Cognitive-behavioral treatment of non-alcoholic fatty liver disease: a propensity score-adjusted observational study. Obesity (Silver Spring) 2011;19:763-70
   Google Scholar
• Esposito K, Pontillo A, Di Palo C, Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003;289:1799-804
   PubMed Web of Science ®Google Scholar
• Rector RS, Warner SO, Liu Y, Exercise and diet induced weight loss improves measures of oxidative stress and insulin sensitivity in adults with characteristics of the metabolic syndrome. Am J Physiol Endocrinol Metab 2007;293:E500-6
   PubMed Web of Science ®Google Scholar
• Tortosa A, Bes-Rastrollo M, Sanchez-Villegas A, Mediterranean diet inversely associated with the incidence of metabolic syndrome: the SUN prospective cohort. Diabetes Care 2007;30:2957-9
   PubMed Web of Science ®Google Scholar
• Lien LF, Brown AJ, Ard JD, Effects of PREMIER lifestyle modifications on participants with and without the metabolic syndrome. Hypertension 2007;50:609-16
   PubMed Web of Science ®Google Scholar
• Zivkovic AM, German JB, Sanyal AJ. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr 2007;86:285-300
   PubMed Web of Science ®Google Scholar
• Ryan MC, Abbasi F, Lamendola C, Serum alanine aminotransferase levels decrease further with carbohydrate than fat restriction in insulin-resistant adults. Diabetes Care 2007;30:1075-80
   Google Scholar
• Ouyang X, Cirillo P, Sautin Y, Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008;48:993-9
   PubMed Web of Science ®Google Scholar
• Le KA, Tappy L, D'Alessio DA. Mitochondrial dysfunction and insulin resistance: a matter of lifestyle? Curr Opin Clin Nutr Metab Care 2007;10:494-7
   Google Scholar
• Johnson JL, Slentz CA, Houmard JA, Exercise training amount and intensity effects on metabolic syndrome (from Studies of a Targeted Risk Reduction Intervention through Defined Exercise). Am J Cardiol 2007;100:1759-66
   PubMed Web of Science ®Google Scholar
• Katzmarzyk PT, Herman KM. The role of physical activity and fitness in the prevention and treatment of metabolic syndrome. Curr Cardiovasc Risk Rep 2007;1:228-36
   Google Scholar
• Johnson NA, Sachinwalla T, Walton DW, Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009;50:1105-12
   PubMed Web of Science ®Google Scholar
• St George A, Bauman A, Johnston A, Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2009;50:68-76
   PubMed Web of Science ®Google Scholar
• Buchwald H, Avidor Y, Braunwald E, Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292:1724-37
   PubMed Web of Science ®Google Scholar
• Meijer RI, van Wagensveld BA, Siegert CE, Bariatric surgery as a novel treatment for type 2 diabetes mellitus: a systematic review. Arch Surg 2011;146:744-50
   Google Scholar
• Bray GA, Ryan DH. Drug treatment of the overweight patient. Gastroenterology 2007;132:2239-52
   PubMed Web of Science ®Google Scholar
• Torgerson JS, Hauptman J, Boldrin MN, XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61
   PubMed Web of Science ®Google Scholar
• Assy N, Hussein O, Abassi Z. Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis. Gut 2007;56:443-4
   PubMed Web of Science ®Google Scholar
• Harrison SA, Fecht W, Brunt EM, Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 2009;49:80-6
   PubMed Web of Science ®Google Scholar
• Sabuncu T, Nazligul Y, Karaoglanoglu M, The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol 2003;12:189-92
   PubMedGoogle Scholar
• Wadden TA, Berkowitz RI, Womble LG, Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005;353:2111-20
   PubMed Web of Science ®Google Scholar
• Torp-Pedersen C, Caterson I, Coutinho W, Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007;28:2915-23
   PubMed Web of Science ®Google Scholar
• Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-34
   PubMed Web of Science ®Google Scholar
• Despres JP, Ross R, Boka G, Effect of rimonabant on the high-triglyceride/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arterioscler Thromb Vasc Biol 2009;29:416-23
   PubMed Web of Science ®Google Scholar
• Bugianesi E, Gentilcore E, Manini R, A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082-90
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Tripathy D, Schwenke DC, Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011;364:1104-15
   PubMed Web of Science ®Google Scholar
• Xiang AH, Peters RK, Kjos SL, Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006;55:517-22
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89
   PubMed Web of Science ®Google Scholar
• Promrat K, Lutchman G, Uwaifo GI, A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39:188-96
   PubMed Web of Science ®Google Scholar
• Belfort R, Harrison SA, Brown K, A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-307
   PubMed Web of Science ®Google Scholar
• Aithal GP, Thomas JA, Kaye PV, Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008;135:1176-84
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Chalasani N, Kowdley KV, Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-85
   PubMed Web of Science ®Google Scholar
• Lewis JD, Ferrara A, Peng T, Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011;34:916-22
   PubMed Web of Science ®Google Scholar
• Piccinni C, Motola D, Marchesini G, Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 2011;34:1369-71
   PubMed Web of Science ®Google Scholar
• Beydoun MA, Shroff MR, Chen X, Serum antioxidant status is associated with metabolic syndrome among U.S. adults in recent national surveys. J Nutr 2011;141:903-13
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Rafiq N, Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011;53:1874-82
   PubMed Web of Science ®Google Scholar
• Madan K, Batra Y, Gupta DS, Vitamin E-based therapy is effective in ameliorating transaminasemia in nonalcoholic fatty liver disease. Indian J Gastroenterol 2005;24:251-5
   PubMedGoogle Scholar
• Dufour JF, Oneta CM, Gonvers JJ, Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006;4:1537-43
   PubMed Web of Science ®Google Scholar
• Balmer ML, Siegrist K, Zimmermann A, Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver Int 2009;29:1184-8
   PubMed Web of Science ®Google Scholar
• Bjelakovic G, Nikolova D, Gluud LL, Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev 2008;CD007176
   Google Scholar
• Rosenstock J, Klaff LJ, Schwartz S, Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 2010;33:1173-5
   PubMed Web of Science ®Google Scholar
• Astrup A, Rossner S, Van Gaal L, Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374:1606-16
   PubMed Web of Science ®Google Scholar
• Gonzalez-Ortiz M, Martinez-Abundis E, Robles-Cervantes JA, Effect of exenatide on fat deposition and a metabolic profile in patients with metabolic syndrome. Metab Syndr Relat Disord 2011;9:31-4
   PubMed Web of Science ®Google Scholar
• Klonoff DC, Buse JB, Nielsen LL, Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275-86
   PubMed Web of Science ®Google Scholar
• Tushuizen ME, Bunck MC, Pouwels PJ, Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int 2006;26:1015-17
   PubMed Web of Science ®Google Scholar
• Yilmaz Y, Atug O, Yonal O, Dipeptidyl peptidase IV inhibitors: therapeutic potential in nonalcoholic fatty liver disease. Med Sci Monit 2009;15:HY1-5
   Google Scholar
• Balaban YH, Korkusuz P, Simsek H, Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann Hepatol 2007;6:242-50
   PubMed Web of Science ®Google Scholar
• Cariou B. The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis. Diabetes Metab 2008;34:685-91
   PubMed Web of Science ®Google Scholar
• Zhang S, Wang J, Liu Q, Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol 2009;51:380-8
   PubMed Web of Science ®Google Scholar
• Ma K, Saha PK, Chan L, Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006;116:1102-9
   PubMed Web of Science ®Google Scholar
• Modica S, Gadaleta RM, Moschetta A. Deciphering the nuclear bile acid receptor FXR paradigm. Nucl Recept Signal 2010;8:e005
   PubMedGoogle Scholar
• Alvarez JA, Ashraf A. Role of vitamin D in insulin secretion and insulin sensitivity for glucose homeostasis. Int J Endocrinol 2010; 2010:351385
   Google Scholar
• Mattila C, Knekt P, Mannisto S, Serum 25-hydroxyvitamin D concentration and subsequent risk of type 2 diabetes. Diabetes Care 2007;30:2569-70
   PubMed Web of Science ®Google Scholar
• Chiu KC, Chu A, Go VL, Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 2004;79:820-5
   PubMed Web of Science ®Google Scholar
• Forouhi NG, Luan J, Cooper A, Baseline serum 25-hydroxy vitamin D is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990 – 2000. Diabetes 2008;57:2619-25
   PubMed Web of Science ®Google Scholar
• Pittas AG, Lau J, Hu FB, The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 2007;92:2017-29
   PubMed Web of Science ®Google Scholar
• Targher G, Bertolini L, Scala L, Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2007;17:517-24
   PubMed Web of Science ®Google Scholar
• Yin J, Zhang H, Ye J. Traditional chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets 2008;8:99-111
   PubMedGoogle Scholar
• Vuddanda PR, Chakraborty S, Singh S. Berberine: a potential phytochemical with multispectrum therapeutic activities. Expert Opin Investig Drugs 2010;19:1297-307
   PubMed Web of Science ®Google Scholar
• Balk EM, Tatsioni A, Lichtenstein AH, Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. Diabetes Care 2007;30:2154-63
   PubMed Web of Science ®Google Scholar
• Suliburska J, Bogdanski P, Pupek-Musialik D, Dietary intake and serum and hair concentrations of minerals and their relationship with serum lipids and glucose levels in hypertensive and obese patients with insulin resistance. Biol Trace Elem Res 2011;139:137-50
   PubMed Web of Science ®Google Scholar
• Obeid O, Elfakhani M, Hlais S, Plasma copper, zinc, and selenium levels and correlates with metabolic syndrome components of lebanese adults. Biol Trace Elem Res 2008;123:58-65
   PubMedGoogle Scholar
• Wijesekara N, Chimienti F, Wheeler MB. Zinc, a regulator of islet function and glucose homeostasis. Diabetes Obes Metab 2009;11(Suppl 4):202-14
   PubMedGoogle Scholar
• Li R, Zhang P, Barker LE, Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care 2010;33:1872-94
   PubMed Web of Science ®Google Scholar
• Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341-50
   PubMed Web of Science ®Google Scholar
• Ratziu V, Bellentani S, Cortez-Pinto H, A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010;53:372-84
   PubMed Web of Science ®Google Scholar
• Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut 2010;59:1410-15
   PubMed Web of Science ®Google Scholar